获取途径

作者

Yipeng Yin Wei Wang Mingbo Tang null Wei Liu

作者单位

²Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Department of Endocrinology, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, Shandong, China ⁵“Chuangxin China” Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, Jinan, 250021, Shandong, China ³Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, 250021, Shandong, China ⁷Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, 250021, Shandong, China ⁴Shandong Institute of Endocrine and Metabolic Diseases, Jinan, 250021, Shandong, China ⁶Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, 250021, Shandong, China ¹Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, 130021, China

刊名

Scientific Reports

年份

2024

卷号

Vol.14

关键词

Tumor size Thymoma Thymic carcinoma SEER program Survival

摘要

This study aims to clarify the impact of tumor size on the prognosis of patients diagnosed with thymoma and thymic carcinoma, leveraging data from a population-based registry. Utilizing the SEER database, this retrospective analysis identified patients diagnosed with thymoma and thymic carcinoma from 2000 to 2020. Propensity score matching was employed to mitigate potential statistical biases between groups categorized by tumor size . The study included a total of 3857 patients, comprising 2688 ...更多

This study aims to clarify the impact of tumor size on the prognosis of patients diagnosed with thymoma and thymic carcinoma, leveraging data from a population-based registry. Utilizing the SEER database, this retrospective analysis identified patients diagnosed with thymoma and thymic carcinoma from 2000 to 2020. Propensity score matching was employed to mitigate potential statistical biases between groups categorized by tumor size . The study included a total of 3857 patients, comprising 2688 with thymoma and 1169 with thymic carcinoma. Multivariate analysis demonstrated that tumors ≤ 6.5 cm independently correlated with improved Cancer-Specific Survival and Overall Survival in both thymoma and thymic carcinoma cohorts. Subgroup analysis revealed that smaller tumors conferred survival benefits in patients with Masaoka-Koga stage IIB thymomas and stage III/IV thymic carcinomas . Additionally, WHO type A/AB/B1 and type B2/B3 thymomas with tumors ≤ 6.5 cm exhibited superior CSS and OS . Through propensity matching analysis utilizing the SEER database, this study underscores the prognostic significance of tumor size in both early-stage thymoma and advanced-stage thymic carcinoma, identifying a critical threshold of 6.5 cm. In the WHO classification, tumor size based on the cut-off value of 6.5 cm has a greater impact on the prognosis of type B2/B3 than A/AB/B1 .收起

文献类型

期刊

浏览量

4